A
Aparna Madhukeshwar Hegde
Researcher at East Carolina University
Publications - 10
Citations - 290
Aparna Madhukeshwar Hegde is an academic researcher from East Carolina University. The author has contributed to research in topics: Lung cancer & Nivolumab. The author has an hindex of 4, co-authored 10 publications receiving 179 citations.
Papers
More filters
Journal ArticleDOI
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade.
Chipman Rg Stroud,Aparna Madhukeshwar Hegde,Cynthia R. Cherry,Abdul Rafeh Naqash,Nitika Sharma,Srikala Addepalli,Sulochana Devi Cherukuri,Teresa Parent,Jessica Hardin,Paul R. Walker +9 more
TL;DR: Tocilizumab may be a therapeutic option for the management of steroid refractory irAEs secondary to immune checkpoint blockade, however, randomized trials are needed to better elucidate the relative efficacy and safety of these agents.
Journal ArticleDOI
Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional database.
Abdul Rafeh Naqash,Chipman Robert Geoffrey Stroud,Muhammad Butt,Grace K. Dy,Aparna Madhukeshwar Hegde,Mahvish Muzaffar,Li V. Yang,Maida Hafiz,Cynthia R. Cherry,Paul R. Walker +9 more
TL;DR: This research presents a novel and scalable approach called “SmartCardiovascular Research,” which aims to provide real-time information about the architecture of the autonomic nervous system and its role in disease progression.
Journal ArticleDOI
Antibiotic use and overall survival in lung cancer patients receiving nivolumab.
Tien Phuc Do,Aparna Madhukeshwar Hegde,Cynthia R. Cherry,Chipman Robert Geoffrey Stroud,Nitika Sharma,Sulochana Devi Cherukuri,Mark R. Bowling,Paul R. Walker +7 more
TL;DR: The gut microbiome modulates immunotherapy responses in multiple tumor types and some studies report antibiotics (ATB) may alter the microbiota composi...
Journal ArticleDOI
Incidence and impact of thromboembolic events in lung cancer patients treated with nivolumab.
Aparna Madhukeshwar Hegde,Chipman Robert Geoffrey Stroud,Cynthia R. Cherry,Meera Yogarajah,Sulochana Devi Cherukuri,Paul R. Walker +5 more
TL;DR: A registry of lung cancer patients with a history of atypical or elevated thromboembolic events followingisplatin-based chemotherapy for atypically high levels of BRCA1/BRCA2 indicates a need for further research into this mechanism.
Journal ArticleDOI
Sequence of stereotactic ablative radiotherapy and immune checkpoint blockade in the treatment of metastatic lung cancer.
Ramya Pinnamaneni,Aparna Madhukeshwar Hegde,Sulochana Devi Cherukuri,Hyder Husain Arastu,Mark R. Bowling,Clinton Leinweber,Chipman Robert Geoffrey Stroud,Cynthia R. Cherry,Paul R. Walker +8 more
TL;DR: Monoclonal antibodies targeting immune checkpoint proteins have recently been shown to elicit robust and durable responses in patients with advanced lung cancer, but with res.e20665 this data indicates that these antibodies may also be applicable to other types of cancer.